Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Up 28.3% in March

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 7,700 shares, a growth of 28.3% from the February 28th total of 6,000 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average trading volume of 12,600 shares, the short-interest ratio is presently 0.6 days.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $7.00 target price on shares of Armata Pharmaceuticals in a report on Thursday, December 19th.

Armata Pharmaceuticals Trading Down 3.0 %

ARMP stock traded down $0.04 during mid-day trading on Friday, reaching $1.28. 9,618 shares of the stock traded hands, compared to its average volume of 11,014. Armata Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $3.85. The firm has a market capitalization of $46.31 million, a PE ratio of -0.78 and a beta of 0.87.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.